VIDEO: Revumenib ‘exciting’ for certain patients with relapsed/refractory AML
Click Here to Manage Email Alerts
SAN DIEGO — In this video, Catherine Lai, MD, MPH, discusses the results from the Augment-101 phase 2 study presented at ASH Annual Meeting and Exposition.
The study assessed the safety and efficacy of revumenib (SNDX-5613, Syndax Pharmaceuticals) among patients with relapsed/refractory KMT2A rearranged acute myeloid leukemia.
“In general, this is a very challenging to treat population and historically has had very dismal outcomes,” Lai, an associate professor and physician leader of the Leukemia Clinical Research Unit at University of Pennsylvania’s Perelman Center for Advanced Medicine, said.
According to the abstract, revumenib demonstrated clinically meaningful results with an overall response rate of 63%.
“This is a very exciting drug for this patient population,” Laid said.
Collapse
Aldoss I, et al. Abstract LBA-5. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
Click Here to Manage Email Alerts